Abstract
Background: Thyroid cancer is the most common endocrine malignancy with poor survival rates for patients with advanced and anaplastic thyroid cancer due to lack of effective therapies. We have previously demonstrated that combined Src and MAPK inhibition results in synergistic inhibition of growth in vitro and in vivo, and increased apoptosis in BRAF- and RAS- mutant cells, while PIK3CA- mutants are resistant. Using a proteomics approach, here we show that the pro-apoptotic protein, BIM, is increased in cells that are sensitive to combined Src and MAPK inhibition compared to cells that are resistant.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
